Response to JAMA Research Letter Regarding Clinicians Offering Stem Cell Treatments

 
The findings of the investigation were troubling, yet not surprising, indicating that many clinicians are providing stem cell treatments for conditions outside of the scope of their training. You can read the full article at this link:
 
The Interventional Orthopedics Foundation (IOF) is dedicated to pioneering and developing the medical sub-specialty of Interventional Orthopedic Medicine by collaborating across medical specialties and bringing together the physicians who are doing the right thing with regenerative medicine. We recognize that achieving this mission requires regulations be put in place to ensure patient safety, including policies that verify stem cell therapies are only being provided by properly trained and licensed clinicians. Accordingly, IOF is advocating for the creation of a standardized registry and educational curriculum to guide our members on the pathway to becoming an orthobiologics expert.
 
IOF President Dr. Gerard Malanga submitted a letter to the editor in response to the research letter published in JAMA to share the organization’s perspective with the medical community. The JAMA editorial staff declined to publish the letter. Please see the full letter below.
 
Dear Editor:
 
It was with great interest that I read the Research Letter published by Fu et all in the recent JAMA Journal (1). I currently serve as the President of the Interventional Orthopedic Foundation (IOF), a nonprofit organization dedicated to educating physicians and developing standards and guidelines for the use of orthobiologics to treat orthopedic conditions. IOF shares the concerns raised in this article regarding clinicians practicing beyond their scope of training and agrees that this practice has become prevalent, increasing risks to patients.
 
The term “stem cell interventions” is quite vague and often used by various centers providing treatments that do not actually contain any type of “stem cells”. IOF recommends procedures be defined to ensure consumers are able to discern which clinicians are offering legitimate treatments. The authors of this report continually describe stem cell therapies as an unproven treatment. While additional research is necessary, to date, the majority of research regarding bone marrow mesenchymal stem cell treatments for knee osteoarthritis in particular has been very positive with an excellent safety profile. Unfortunately, this scientific evidence of efficacy has been hijacked by unscrupulous clinicians using less than adequate and unstandardized technique, with a few of these centers providing treatment that amounts to medical malpractice.
 
As in any area of medicine, treatments that are improperly performed without attention to standards and guidelines will result in the potential for serious complications. It is therefore critical that any treatment, in particular new and innovative treatment, is performed with appropriate training, standards and guidelines. IOF is advocating for the creation of a standardized national registry database to ensure clinicians using the highest level of techniques are able to collect the outcomes of these treatments and establish their efficacy. A national registry will empower clinicians using research-based techniques while dissuading those who wish to take advantage of vulnerable patient populations by using non-standardized techniques and slick marketing to sell procedures that are ineffective at best and deadly at worst.
 
Ultimately, treatments that are in the best interest of the patient will be offered and provided using the best available techniques.
 
Sincerely,
Gerard A. Malanga, MD
President, Interventional Orthopedic Foundation (IOF)

You Might Also Enjoy...

Clinical Trial for Knee Osteoarthritis

We are pleased to announce that New Jersey Regenerative Institute has been selected for participation in a first of its kind investigational stem cell clinical trial for knee osteoarthritis.